drugset / Trial / NCT00572663

Optimalization of Nephroprotection Using N-Acetylcysteine

NCT00572663

RandomizedCrossoverOpen-labelTreatment

Summary

The main purpose of the study is find whether the addition of N-acetylcysteine (antioxidant) to dual renin-angiotensin-aldosterone system blockade involving angiotensin converting enzyme inhibitor and AT-1 angiotensin II receptor blocker leads to the reduction of proteinuria, main prognostic marker of chronic kidney disease progression.

Timeline

Start
2005-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 1200 mg